SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS Pharmaceuticals, Inc. (“ARS Pharmaceuticals”) to offer the lowest discounted cash price for neffy® in retail pharmacy locations. Available for purchase in-store this week, consumers who have been prescribed neffy can now access a pack of two single-use neffy devices for $199 at more than 70,000 pharmacies nationwide exclusively through GoodRx..

加利福尼亚州圣莫尼卡（商业新闻短讯）--美国领先的处方储蓄平台GoodRx（纳斯达克：GDRX）今天宣布，它正在与ARS Pharmaceuticals，Inc.（“ARS Pharmaceuticals”）合作，为零售药店的neffy®提供最低折扣现金价格。本周可在商店购买，开过neffy处方的消费者现在可以通过GoodRx独家在全国70000多家药店以199美元的价格购买一包两个一次性使用的neffy设备。。

Approved by the Food and Drug Administration in August, neffy is the first needle-free treatment for Type I allergic reactions, including anaphylaxis, offering an innovative alternative to auto-injectors. Unlike traditional methods, neffy delivers epinephrine nasally, avoiding needle injections.

8月，美国食品和药物管理局（FDA）批准了neffy，它是第一种针对I型过敏反应（包括过敏反应）的无针治疗方法，为自动注射器提供了一种创新的替代品。与传统方法不同，neffy通过鼻腔输送肾上腺素，避免了针头注射。

'At GoodRx, we’re not just motivated by making essential medications more accessible and affordable, but also by championing innovation within well-established markets,' said Dorothy Gemmell, Chief Commercial Officer at GoodRx. “We’re committed to offering neffy at a lower price so we can help break down long-standing barriers in anaphylaxis treatment and offer an option that millions of people, especially children and adults who need to carry epinephrine, can use to receive timely and effective treatment.”.

GoodRx首席商务官多萝西·杰梅尔（DorothyGemmell）说：“在GoodRx，我们的动机不仅是让基本药物更容易获得和负担得起，而且是在成熟的市场中倡导创新。”。“我们致力于以较低的价格提供neffy，因此我们可以帮助打破过敏反应治疗中长期存在的障碍，并为数百万人，特别是需要携带肾上腺素的儿童和成年人提供一种选择，以获得及时有效的治疗。”。

Allergies and allergy symptoms impact over 100 million Americans annually, with more than 50 million experiencing an allergic reaction each year, underscoring the critical need for accessible treatment. Anaphylaxis, a severe allergic reaction involving the whole body, can induce symptoms such as difficulty breathing, fast heartbeat, hives, nausea, and in severe cases, loss of consciousness, often occurring within seconds or minutes of exposure to an allergen.

过敏和过敏症状每年影响1亿多美国人，每年有5000多万人经历过敏反应，这突显了对可获得治疗的迫切需求。过敏反应是一种涉及全身的严重过敏反应，可引起呼吸困难，心跳加快，荨麻疹，恶心等症状，严重时还会导致意识丧失，通常在接触过敏原的几秒钟或几分钟内发生。

neffy provides a much-needed option that enhances accessibility and affordability for millions of Americans..

neffy提供了一个急需的选项，可以增强数百万美国人的可用性和负担能力。。

“We’re thrilled about neffy’s U.S. Food and Drug Administration approval, so people with severe allergies don’t have to endure needle-injection of epinephrine, which can be fraught with anxiety and fear, and can carry a device that’s small and effective. Through our partnership with GoodRx, we can offer our innovation in retail pharmacies along with patient programs to support its affordability,” said Richard Lowenthal, Co-Founder, President, and Chief Executive Officer of ARS Pharmaceuticals.

ARS Pharmaceuticals联合创始人、总裁兼首席执行官理查德·洛文塔尔（Richard Lowenthal）表示：“我们对内菲获得美国食品和药物管理局（FDA）的批准感到兴奋，因此严重过敏的人不必忍受肾上腺素的针头注射，肾上腺素可能充满焦虑和恐惧，并且可以携带小巧有效的设备。通过我们与GoodRx的合作，我们可以提供零售药店的创新以及患者计划，以支持其负担能力。”。

'We’re grateful that GoodRx’s platform has helped us reach more patients and caregivers to access a needle-free option so they can respond swiftly during a Type 1 allergic reaction.”.

“我们很感谢GoodRx的平台帮助我们接触到更多的患者和护理人员，让他们能够获得无针选项，以便他们在1型过敏反应期间迅速做出反应。”。

By partnering with nearly 150 brands across pharmaceutical manufacturers, medical device companies, and OTC medicines, GoodRx directly links savings and patient support programs to high-intent audiences through its platform, enhancing access to more cost-effective treatments across the healthcare industry.

通过与制药商、医疗器械公司和非处方药的近150个品牌合作，GoodRx通过其平台直接将储蓄和患者支持计划与高意向受众联系起来，从而增强了整个医疗保健行业获得更具成本效益的治疗的机会。

The company recently announced an affordability program with Boehringer Ingelheim to provide its Humira® biosimilar (adalimumab) at a low cash price available exclusively on GoodRx. Similarly, the company has partnered with Sanofi to offer its insulin Lantus at just $35..

该公司最近宣布与勃林格殷格翰（Boehringer Ingelheim）合作实施一项可负担性计划，以低现金价格提供其Humira®生物仿制药（阿达木单抗），仅在GoodRx上提供。同样，该公司已与赛诺菲合作，以35美元的价格提供其胰岛素Lantus。。

Consumers can access the savings on neffy at www.goodrx.com/neffy

消费者可以在www.goodrx.com/neffy上获得neffy的节省

For Important Safety Information, please see neffy.com and full Patient Information

有关重要的安全信息，请参阅neffy.com和完整的患者信息

About GoodRx

关于GoodRx

GoodRx is the leading prescription savings platform in the U.S. Trusted by more than 25 million consumers and 750,000 healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information.

GoodRx是美国领先的处方储蓄平台。GoodRx每年受到2500多万消费者和750000名医疗保健专业人员的信任。GoodRx在全国70000多家药店提供仿制药和名牌药物的储蓄和可负担性选择，以及全面的医疗保健研究和信息。

Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions..

自2011年以来，GoodRx帮助消费者节省了超过750亿美元的处方费用。。

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts.

GoodRx定期在其投资者关系网站上发布对投资者可能重要的信息https://investors.goodrx.com.我们打算将我们的网站用作披露重大非公开信息的手段，并遵守FD法规规定的披露义务。因此，鼓励投资者和潜在投资者定期访问GoodRx的网站以获取重要信息，此外，还应关注GoodRx的新闻稿、向证券交易委员会（“SEC”）提交的文件以及公开电话会议和网络广播。

The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release..

GoodRx网站上包含的或可通过GoodRx网站访问的信息未通过引用纳入本新闻稿，也不属于本新闻稿的一部分。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings and accessibility; the expected benefits and value of our partnership with ARS Pharmaceuticals and GoodRx’s other offerings; and our plans, expectations and objectives.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。本新闻稿中包含的所有与历史事实无关的声明均应视为前瞻性声明，包括但不限于有关预期消费者储蓄和可及性的声明；我们与ARS Pharmaceuticals和GoodRx的其他产品合作的预期收益和价值；。

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC.

这些声明既不是承诺也不是保证，但涉及已知和未知的风险、不确定性和其他重要因素，这些因素可能导致我们的实际结果、业绩或成就与前瞻性声明明示或暗示的任何未来结果、业绩或成绩有重大差异，包括但不限于与我们实现广泛市场教育和改变消费者购买习惯的能力有关的风险；药物定价和定价结构的变化；我们依赖数量有限的行业参与者；以及我们在截至2023年12月31日的10-K表年度报告以及我们向SEC提交的其他文件中，在“风险因素”标题下讨论的重要因素。

Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change..

任何此类前瞻性声明均基于截至本新闻稿发布之日的当前预期、预测和估计。虽然我们可能会选择在未来某个时候更新此类前瞻性声明，但我们不承担任何义务，即使后续事件导致我们的观点发生变化。。